Center for Psychedelic Medicine Founded at NYU Langone Health

NEW YORK, Feb. 25: Philanthropic support from a number of donors totaling in excess of $10 million will enable NYU Langone Health to enhance its already globally-famous reputation in the sphere of psychedelic medicine via the establishment of a one-of-a-kind center devoted to increasing research and specialised medical training in this resurging field. When fully developed, the NYU Langone Center for Psychedelic Medicine, under the auspices of NYU Langone's Department of Psychiatry, will support health-focused research across the translational spectrum, from basic science to Phase III clinical trials. Principally, it will have three transdisciplinary areas of focus: psychiatry, medicine and preclinical research. In addition, a robust training program, the Psychedelic Medicine Research Training Program -- which differentiates this center from others – will support the development of early career faculty members and post-doctoral fellows to become independent investigators in the field of psychedelic medicine. In addition, the Psychedelic Medicine Research Training Program aims to work with members of the psychedelic medicine industry to develop treatment models and training programs to help to scale psychedelic medicines into mainstream adoption by psychiatrists and therapists in America. "These initiatives will provide an environment in which scientists, clinicians, trainees and other staff contribute in meaningful ways to ensure that the momentum created by the modern psychedelic renaissance is sustained and continues to yield medical breakthroughs backed by sound science," says Michael P. Bogenschutz, MD, Professor of Psychiatry at NYU Grossman School of Medicine, and an acknowledged leader in the field of psychedelic medicine who will serve as the Center's director. Another unique aspect of the NYU Langone Center for Psychedelic Medicine is its commitment to move beyond the confines of psychiatry, expanding its focus into clinical applications across other health disciplines. "Our broad focus on discovery for medical applications of psychedelics places NYU Langone at the vanguard of research on many difficult-to-treat psychiatric and medical disorders," says Stephen Ross, MD, associate professor of Psychiatry at NYU Grossman School of Medicine, and a fellow leader in the field who will serve as the Center's associate director. "Moreover, we plan to utilize this health-focused structure to provide important training opportunities to sustain high-quality psychedelic research."